Introduction {#Sec1}
============

Gastroesophageal reflux occurs naturally in healthy infants, children, and adults without troublesome consequences \[[@CR1]\]. Gastroesophageal reflux disease (GERD) is characterized by reflux of gastric contents that causes persistent symptoms such as heartburn, cough, epigastric pain, vomiting, and regurgitation. Troublesome symptoms associated with GERD are perceived by both the patient (over 8 years of age) and the patient's caretaker \[[@CR2]\]. GERD has been proposed to exist as 5 distinct presentations: functional heartburn, hypersensitive esophagus, non-erosive GERD, erosive esophagitis (EE), and Barrett's esophagus. These phenotypes are clinically distinct rather than continuous, despite the similarity of symptoms among them \[[@CR3]\]. Further, GERD symptoms in isolation cannot reliably predict EE, and symptom severity does not correlate with the degree of mucosal injury. Since GERD symptoms cannot predict endoscopic findings, an EE diagnosis requires visual evidence of breaks in the esophageal mucosa above the gastroesophageal junction \[[@CR4], [@CR5]\].

GERD evolves over time in children and adolescents, with frequency of heartburn symptoms and prevalence of EE increasing with age. Although evidence is limited, one study reported the incidence of endoscopically confirmed EE as 10.5% in 12-year-olds with GERD and 19.5% in 17-year-olds. The individual symptom prevalence of heartburn in the general pediatric population was 1.8% in 3- to 9-year-olds, 3.5% in 10- to 17-year-olds, and 22% in over 18-year-olds \[[@CR6]\], while a survey of 615 children aged 10--17 years reported the prevalence of at least weekly heartburn to be 5--8% \[[@CR7], [@CR8]\]. Prevalence rates of EE are higher in pediatric patients with underlying disorders such as neurologic impairment or repaired esophageal atresia; thus, children with persistent GERD symptoms, as well as GERD-promoting underlying conditions, are candidates for empiric proton pump inhibitor (PPI) treatment \[[@CR1], [@CR2]\].

Extensive evidence suggests that short-term (e.g., 8 weeks) treatment with PPIs such as omeprazole, esomeprazole, lansoprazole, rabeprazole, and pantoprazole is efficacious for healing EE and improving symptoms in children aged 1--17 years \[[@CR9]--[@CR15]\]. Clinical practice guidelines recommend PPIs as first-line therapy for up to 3 months for healing of EE in children, on the basis of expert opinion \[[@CR1]\]. However, the need for maintenance PPI therapy in healed EE for pediatric patients without underlying conditions has been challenged, as relapse rates after healing vary from 2.2 to 25% \[[@CR1], [@CR16], [@CR17]\]. Higher relapse rates were observed in a greater proportion of patients with more severe grades of esophagitis or those with coexisting disorders that predispose to GERD \[[@CR1], [@CR17]\]. These studies suggest that maintenance PPI therapy may be needed more in patients with higher grades of EE and/or underlying conditions \[[@CR1], [@CR17]\].

In 2009, the PPI dexlansoprazole (DEXILANT^®^, Takeda Pharmaceuticals U.S.A., Inc.) capsule was approved at a 30-mg daily dose for adults to relieve heartburn, to maintain healed EE, and for relief of heartburn for up to 6 months, and to treat heartburn associated with symptomatic non-erosive GERD for 4 weeks. A daily dose of 60 mg for up to 8 weeks was approved for the healing of EE \[[@CR18]\]. In 2016, dexlansoprazole was approved for patients aged 12--17 years with GERD. Dexlansoprazole is an enantiomer of lansoprazole with a unique dual delayed-release formulation designed to extend the duration of drug exposure and resulting gastric acid suppression \[[@CR18], [@CR19]\]. After ingestion, an initial set of granules releases 25% of the drug dose on dissolution of the enteric coating when pH is ≥ 5.5, which occurs in the proximal duodenum. The second set of granules releases the remaining 75% of the dexlansoprazole dose further along the gastrointestinal tract when pH is ≥ 6.75 \[[@CR19], [@CR20]\]. In a study of adult patients, EE healing rates for a 60-mg daily dose of dexlansoprazole were superior to 30-mg lansoprazole (85.3% vs. 79.0%; *P *= 0.05), although another study reported no difference in EE healing (60 mg dexlansoprazole: 86.9%; 30 mg lansoprazole 84.6%) \[[@CR21]\]. After EE healing, dexlansoprazole has also shown efficacy at 30- and 60-mg once-daily doses in maintaining healed EE for up to 6 months and in controlling heartburn for greater than 90% of treatment days \[[@CR22]\]. A similar pharmacokinetic profile of once-daily dexlansoprazole has been observed in adolescents \[[@CR23]\]. In the present trial, we investigated the safety, tolerability, and efficacy of dexlansoprazole for EE healing and maintenance of healed EE in adolescents with confirmed EE. These findings have practical implications for the treatment of GERD in pediatric and adolescent populations. Because GERD symptoms, and more importantly, GERD-related mucosal injury can carry over to adulthood \[[@CR24]\], efforts to control or prevent further esophageal damage and improve quality of life are important for these young patients.

Methods {#Sec2}
=======

This international phase 2, multicenter, 36-week trial was designed to assess the safety and efficacy of dexlansoprazole treatment in adolescents (aged 12--17 years) with EE. The trial (EudraCT number: 2012-001681-15) was conducted from June 22, 2012, to November 10, 2014, and enrolled patients from 18 international sites, including 8 in the USA, 6 in Poland, 3 in Portugal, and 1 in Mexico (range per site 1--12). Study protocols were in accordance with the Declaration of Helsinki and the International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP) \[[@CR25], [@CR26]\]. Before the initiation of study procedures, written consent was obtained from the parent or guardian, and assent was obtained from all adolescents.

This study protocol was in compliance with the Institutional Review Board regulations stated in Title 21 of the United States Code of Federal Regulations, Part 56, GCP regulations and guidelines, and all applicable local regulations.

Study Participants {#Sec3}
------------------

A total of 237 adolescents were screened for the study and an accompanying trial that assessed adolescents with symptomatic non-erosive GERD (EudraCT number: 2012-001680-72). The study aimed to enroll 60 patients with endoscopically confirmed EE and a history of GERD symptoms for at least 3 months before screening. Throughout the screening, treatment, and follow-up periods, patients documented the presence of heartburn symptoms in the morning and at night each day in an electronic diary (eDiary). Patients who reported heartburn on at least 3 of any 7 days during screening were scheduled for endoscopic confirmation of EE before receiving treatment. Based on the Los Angeles (LA) Classification Grading System, EE severity of grade A, B, C, or D was required for study entry \[[@CR27]\]. Endoscopies performed within a week before entering the study and 2 weeks before the beginning of the treatment phase were used if the procedures met minimum protocol requirements. Fasting serum gastrin levels were measured in all patients during the screening period, weeks 4 and 8 of the open-label phase, and weeks 16, 24, 32, and 36 of the maintenance phase.

Gastric mucosa biopsies (stomach antrum and fundus) were taken during the screening endoscopy to detect the presence of *Helicobacter pylori*, and positive patients were excluded from the study. Adolescents with evidence of disease, symptoms, or abnormal laboratory values that suggested a clinically significant, uncontrolled underlying condition (other than GERD or EE) that could potentially confound study results were also excluded; examples include any coexisting disease affecting the esophagus, Barrett's esophagus with dysplastic changes, eosinophilic esophagitis (EoE) or endoscopic findings suggestive of EoE, celiac disease, or positive tissue transglutaminase antibody test, active duodenal or gastric ulcers, human immunodeficiency virus (HIV), cancer (except basal cell carcinoma) within 5 years of screening, or Zollinger--Ellison syndrome or another hypersecretory condition. Patients with hypersensitivity or allergies to dexlansoprazole, any component of dexlansoprazole or other PPI, or antacid containing Mg(OH)~2~ and/or Al(OH)~3~ or simethicone were excluded, as well as any patients who had taken a PPI within 1 week of their screening visit, or who participated in another clinical study, and/or received any investigational compound within 30 days before screening. In addition, patients who received or were planning to receive prohibited medications (e.g., histamine-2 receptor antagonists \[H2RAs\], non-site-supplied antacids or PPIs, nonsteroidal anti-inflammatory drugs, corticosteroids, misoprostol, anticoagulants, antiplatelet therapy, or drugs with significant anticholinergic effects) were also excluded from the study.

Study Design {#Sec4}
------------

The study consisted of 3 periods: screening (up to 21 days), treatment (8-week open-label healing phase, 16-week double-blind maintenance phase), and follow-up (3 months) (Fig. [1](#Fig1){ref-type="fig"}). Patients were instructed that lifestyle or behavior modifications for managing GERD symptoms should not be altered throughout the study. Adolescents with endoscopically confirmed EE were enrolled into the open-label healing phase and were given dexlansoprazole delayed-release 60-mg capsules administered orally once a day (QD) for 8 weeks (Fig. [1](#Fig1){ref-type="fig"}). At week 8, an endoscopy was performed to assess healing of EE. Patients with confirmed healing were randomized (1:1) to receive daily administration of either a dexlansoprazole 30-mg capsule or placebo QD for the next 16 weeks to assess healed EE maintenance. Patients without healing at week 8 were discontinued from the study. Randomization during the maintenance phase of the study was scheduled using the interactive voice/web response system. Patients were re-assessed by endoscopy at week 24 after completion of the double-blind maintenance phase (Fig. [1](#Fig1){ref-type="fig"}). Patients who had relapsed EE at the end of the treatment phase were discontinued, and those with maintenance of healed EE returned to the clinic monthly during the follow-up period to assess recurrence of symptoms and relapse of EE. Study drug adherence was calculated by capsule count (total count of capsules taken/total number of days on study drug) separately for the healing and maintenance phases.Fig. 1Study design. The study included 4 periods: screening (up to 21 days), an open-label healing phase (8 weeks), a double-blind maintenance phase (16 weeks), and a posttreatment follow-up phase (up to 3 months). EE healing was assessed at week 8 and week 24 by endoscopy. *EE* erosive esophagitis, *QD* once daily

Endpoints {#Sec5}
---------

Primary endpoints were any treatment-emergent adverse events (TEAEs) observed in ≥ 5% of patients during the healing and maintenance phases. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA; version 10.0 International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland), and those that were determined to be related to the study drug by the investigator were termed treatment-related adverse events (TRAEs) \[[@CR28]\]. Safety was assessed through adverse event assessments, physical examinations, monitoring of vital signs, routine laboratory evaluations, and standard 12-lead electrocardiograms. Secondary endpoints included the percentages of patients with healing of EE at week 8 and with maintenance of healed EE at week 24 (as assessed by endoscopy) and the percentage of days with neither daytime nor nighttime heartburn after treatment in the healing and maintenance phases (as assessed by eDiary). The rates of healing of EE at week 8 and maintenance of healed EE at week 24 were presented along with 95% exact confidence intervals (CIs).

Additional endpoints included the investigator-rated severity of GERD symptoms, and the severity of daytime and nighttime heartburn (0 = no heartburn, 1 = did not hurt very much, 2 = hurt some, and 3 = hurt a lot), along with the percentage of days without nighttime heartburn and without rescue medication during the open-label and double-blind phases recorded via eDiary (Supplemental Table S1). Investigator-rated severity of GERD symptoms was evaluated at weeks 4, 8, 16, and 24. Efficacy was evaluated by endoscopy, eDiary entry, and investigator assessment of GERD. Statistical analyses were performed using SAS version 9.2 software. Summary statistics (mean, median, number, or percentage) were calculated for variables such as baseline age, height, weight, and body mass index (BMI). During the double-blind phase, the placebo and dexlansoprazole groups were compared with Fisher's exact test for the percentage of patients with maintenance of healed EE at week 24 and with Wilcoxon rank-sum tests for the percentage of days with neither daytime nor nighttime heartburn, without nighttime heartburn, and without daytime heartburn.

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

At the beginning of the study, the majority of patients had baseline EE grades of either A or B (Table [1](#Tab1){ref-type="table"}). Two patients had baseline EE grades of C or D for healing phase. Constipation (4.8%) and pneumonia (4.8%) were the most commonly reported medical history; in addition, 4.8% of patients had previously undergone esophagogastroduodenoscopy. Among patients who entered the maintenance phase, all but one had baseline EE grades of either A or B; one patient in the placebo group had baseline EE of grade C. Other baseline characteristics between patients assigned to the dexlansoprazole and placebo treatment groups were similar (Table [1](#Tab1){ref-type="table"}). Gastric biopsies were normal in 64.5% of the patients, with chronic gastritis as the most common abnormal finding in the absence of *H. pylori* (33.9% of all patients).Table 1Baseline patient characteristicsCharacteristicOpen-label healing phaseDouble-blind maintenance phaseDexlansoprazole 60 mg QD (*n* = 62)Placebo (*n* = 26)Dexlansoprazole 30 mg QD (*n *= 25)Age Years, mean ± SD14.8 ± 1.6414.8 ± 1.7514.6 ± 1.41 12--14 years \[*n* (%)\]24 (38.7)11 (42.3)10 (40.0) 15--17 years \[*n* (%)\]38 (61.3)15 (57.7)15 (60.0) Sex (male) \[*n* (%)\]38 (61.3)16 (61.5)14 (56.0)Race White \[*n* (%)\]61 (98.4)25 (96.2)25 (100.0) Black/African American \[*n* (%)\]1 (1.6)1 (3.8)0 Weight (kg), mean ± SD61.86 ± 17.0661.17 ± 16.1362.63 ± 16.67 Height (cm), mean ± SD165.5 ± 9.68166.5 ± 10.60164.8 ± 7.46 BMI (kg/m^2^)22.34 ± 5.0921.89 ± 4.8022.88 ± 5.11Smoking classification \[*n* (%)\] Never smoked61 (98.4)26 (100.0)24 (96.0) Current smoker1 (1.6)01 (4.0)*H. pylori* status \[*n* (%)\] Positive000 Negative61 (98.4)26 (100.0)24 (96.0) Unknown1 (1.6)01 (4.0)Baseline EE grade^a^ (LA classification^b^) \[*n* (%)\] Grade A34 (54.8)16 (61.5)14 (56.0) Grade B26 (41.9)9 (34.6)11 (44.0) Grade C1 (1.6)1 (3.8)0 Grade D1 (1.6)00*BMI* body mass index, *EE* erosive esophagitis, *LA* Los Angeles, *QD* once daily, *SD* standard deviation^a^Baseline grades of EE severity were evaluated during the screening period^b^Grade A: One (or more) mucosal break ≤ 5 mm long that does not extend between the tops of two mucosal folds; Grade B: One (or more) mucosal break \> 5 mm long that does not extend between the tops of two mucosal folds; Grade C: One (or more) mucosal break that is continuous between the tops of two or more mucosal folds but that involves \< 75% of the circumference; Grade D: One (or more) mucosal break that involves ≥ 75% of the esophageal circumference

Patient-reported heartburn frequency, severity, and rescue medication use measured during the 7 days prior to the open-label healing phase and investigator-rated GERD symptom severity at baseline are shown in Table [2](#Tab2){ref-type="table"}. The frequency and severity of heartburn were greater during the day than at night during the week prior to initiating treatment (Table [2](#Tab2){ref-type="table"}). Investigator-rated GERD symptom severity at baseline was mild or moderate in most patients. Heartburn and epigastric pain were the most commonly observed symptoms, occurring in 76% and 73% of patients, respectively (Table [2](#Tab2){ref-type="table"}).Table 2Disease characteristics in patients during the 7 days prior to starting the open-label healing phasePatient-rated disease characteristic (*N* = 62)Heartburn (days), mean ± SD^a^Daytime/nighttime heartburn4.8 ± 2.07Nighttime heartburn3.0 ± 2.24Daytime heartburn4.3 ± 2.09Heartburn (severity), mean ± SD^a,b^Daytime/nighttime heartburn1.03 ± 0.713Nighttime heartburn0.87 ± 0.746Daytime heartburn1.21 ± 0.743Rescue medication use (days), mean ± SD^a^1.6 ± 1.67Symptom \[*n* (%)\]Investigator-rated GERD symptom severityNoneMildModerateSevereVery severeHeartburn13 (21.0)16 (25.8)23 (37.1)8 (12.9)0Acid regurgitation19 (30.6)18 (29.0)16 (25.8)7 (11.3)1 (1.6)Dysphagia49 (79.0)4 (6.5)7 (11.3)00Belching22 (35.5)16 (25.8)14 (22.6)7 (11.3)1 (1.6)Epigastric pain15 (24.2)14 (22.6)18 (29.0)12 (19.4)1 (1.6)*eDiary* electronic diary, *GERD* gastroesophageal reflux disease, *SD* standard deviation^a^Derived from eDiary data^b^Scale for severity: 0 = none, 1 = did not hurt very much, 2 = hurt some, 3 = hurt a lot

Of the 62 patients with EE initially selected to participate in the open-label healing phase (median study drug exposure, 56 days), 51 patients had documented healing at week 8 and entered the double-blind maintenance phase (Supplemental Figure S1). Four patients were unable to complete the healing phase, and 7 patients with unhealed EE were excluded from the maintenance phase (Supplemental Figure S1). During the maintenance phase, 22 and 24 patients were evaluable for maintenance of EE healing in the dexlansoprazole and placebo groups, respectively. A total of 38 patients completed this phase (median study drug exposure, 112 days in both dexlansoprazole and placebo groups). Patients who maintained healing at the end of the 16-week double-blind phase discontinued study drug and were monitored for a follow-up period of up to 3 months (Supplemental Figure S1). Twenty-four patients completed the follow-up phase. Mean adherence rates of 95% and 96% were reported in the open-label healing phase and double-blind maintenance phase, respectively.

Safety {#Sec8}
------

Most TEAEs across both phases of the study were considered mild or moderate in intensity (Table [3](#Tab3){ref-type="table"}), and no deaths were reported. During the open-label healing phase, 38 patients (61.3%) reported a total of 79 TEAEs (Table [3](#Tab3){ref-type="table"}), and none were considered related to treatment. Headache (12.9%) was the most commonly reported TEAE in the healing phase, followed by oropharyngeal pain (8.1%), diarrhea (6.5%), and nasopharyngitis (6.5%). One patient experienced serious TEAEs, including substance abuse, during the healing phase and deliberate poisoning with diclofenac later during the follow-up period.Table 3Treatment-emergent adverse eventsAEOpen-label healing phase\
Dexlansoprazole 60 mg QD (*n* = 62)Double-blind maintenance phasePlacebo (*n* = 26)Dexlansoprazole 30 mg QD (*n* = 25)Events, *n*Patients \[*n* (%)\]Events (*n*)Patients, \[*n* (%)\]Events (*n*)Patients, \[*n* (%)\]Any AE7938 (61.3)4616 (61.5)4518 (72.0)Mild6229 (46.8)358 (30.8)3711 (44.0)Moderate168 (12.9)107 (26.9)76 (24.0)Severe11 (1.6)11 (3.8)11 (4.0)Any AE leading to discontinuation11 (1.6)0011 (4.0)Any serious AE11 (1.6)11 (3.8)22 (8.0)Common AE (reported by ≥ 5% of patients in any treatment group) \[*n* (%)\]Headache8 (12.9)4 (15.4)6 (24.0)Oropharyngeal pain5 (8.1)1 (3.8)1 (4.0)Diarrhea4 (6.5)2 (7.7)0Nasopharyngitis4 (6.5)4 (15.4)3 (12.0)Abdominal pain3 (4.8)3 (11.5)3 (12.0)Pharyngitis3 (4.8)03 (12.0)Upper respiratory tract infection2 (3.2)02 (8.0)Abdominal pain upper1 (1.6)2 (7.7)1 (4.0)Bronchitis1 (1.6)1 (3.8)2 (8.0)Insomnia1 (1.6)02 (8.0)Sinusitis1 (1.6)03 (12.0)Erosive esophagitis02 (7.7)1 (4.0)Pyrexia02 (7.7)0*AE* adverse events, *QD* once daily

During the maintenance phase, 18 patients receiving dexlansoprazole (72.0%) and 16 patients receiving placebo (61.5%) reported a total of 45 and 46 TEAEs, respectively (Table [3](#Tab3){ref-type="table"}). As in the healing phase, headache was the most commonly reported TEAE by both treatment groups in the maintenance phase, with 6 (24.0%) dexlansoprazole-treated patients and 4 (15.4%) placebo-exposed patients experiencing this event. In addition to headache, other TEAEs experienced by ≥ 5% of patients in the dexlansoprazole treatment group included abdominal pain, nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection, bronchitis, and insomnia (Table [3](#Tab3){ref-type="table"}). Three TEAEs during the maintenance phase were considered serious and included a case each of convulsion (dexlansoprazole), recurrence of GERD (dexlansoprazole), and H1N1 influenza (placebo). Only the recurrence of GERD led to study discontinuation, and the event was considered by investigators to be related to the study drug. This patient had healing of grade A EE at week 8, but after hospitalization for stomach pain 10 weeks later, a follow-up endoscopy revealed reoccurrence of grade A EE. Two other TEAEs in the dexlansoprazole treatment group were considered to be treatment-related: abdominal pain (1 patient) and decreased appetite (1 patient). Twelve (67%) and 5 (36%) patients who had received dexlansoprazole maintenance treatment or placebo, respectively, experienced TEAEs during the treatment-free follow-up period (data not shown). No clinically concerning results were noted in the clinical laboratory, vital signs, ECG, or physical examination assessments.

Mean increase in serum gastrin was 64.1 pg/mL after 4 weeks of the open-label healing phase, and mean levels remained stable during the subsequent 4 weeks of this phase. During the maintenance phase, mean serum gastrin levels for subjects in the placebo group decreased to near-baseline levels by 8 weeks and remained at this level. In the 30-mg dexlansoprazole group, mean serum gastrin values decreased by 7.4 pg/mL after 8 weeks and 19.0 pg/mL after 16 weeks. None of the patients in the dexlansoprazole group in the maintenance phase had elevated levels during the follow-up period.

Efficacy {#Sec9}
--------

### EE Healing Phase {#Sec10}

After 8 weeks of treatment with dexlansoprazole 60 mg QD, 88% of evaluable patients in the open-label phase had healed EE (95% CI: 76.7, 95.0) (Fig. [2](#Fig2){ref-type="fig"}a). In the intent-to-treat population, healed EE was observed in 82% (95% CI: 70.5, 90.8) of patients enrolled in the 8-week open-label phase. Of the 7 patients whose EE persisted, 3 had EE that stayed at the same grade, 3 patients saw improvements (from grade B to A in 2 patients and from grade D to B in another), and 1 worsened (from grade B to C). Overall adherence among these patients was 85--100%. Healing was achieved in 94% of patients with a baseline EE grade of A, while a healing rate of 83% was observed in patients with a baseline EE grade of B (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Evaluation of EE healing and maintenance of healed EE. Percentages of patients with **a** healed EE at week 8 after administration of dexlansoprazole 60 mg in the open-label phase and **b** maintenance of healed EE at week 24 during the double-blind phase. Error bars represent 95% confidence intervals. ^a^Percentages are based on the number of subjects that have results at week 24. *EE* erosive esophagitis, *LA* Los Angeles

During the open-label healing phase, daytime heartburn was more common than nighttime heartburn; heartburn was absent for a median 73.9% of days and 85.4% of nights. Patients spent a median 65.8% of days during the 8-week open-label healing phase with neither daytime nor nighttime heartburn. The median percentage of days that patients did not use rescue medication in the open-label healing phase was 96.6%.

### Maintenance of Healed EE Phase {#Sec11}

Maintenance of healed EE at the end of the 16-week double-blind phase was evaluable in 22 and 24 patients in dexlansoprazole 30 mg QD and placebo groups, respectively. Maintenance of healed EE at the end of the 16-week double-blind maintenance phase was achieved in 82% (18/22 patients, 95% CI: 59.7, 94.8; *P* value vs. placebo 0.114) and 58% (14/24 patients, 95% CI: 36.6, 77.9) of evaluable patients receiving dexlansoprazole 30 mg QD (*n *= 22) and placebo (*n* = 24), respectively (Fig. [2](#Fig2){ref-type="fig"}b). In the intent-to-treat population, maintenance of healed EE was observed in 72% (95% CI: 50.6, 87.9; *P* value vs. placebo 0.249) and 54% (95% CI: 33.4, 73.4) of patients randomized to dexlansoprazole 30 mg QD and placebo, respectively. Four patients relapsed with dexlansoprazole 30 mg QD: 3 patients returned to the same EE grade as they had at baseline, while 1 patient worsened from a baseline grade of B to grade C. The latter patient whose EE worsened had an adherence rate of 77.1%, while adherence rates for the prior 3 patients ranged from 85.7 to 100%.

Ten patients on placebo had a relapse of EE with 4 returning to their baseline EE grade of B and 2 patients returning to their baseline EE grade of A. Four patients relapsed to a less severe EE grade than at baseline: 3 patients who had an EE of grade B at baseline relapsed to grade A, and 1 patient who had an EE of grade C at baseline relapsed to grade B.

Among patients with EE of grade A at baseline, similar rates of maintained healing were seen between those receiving dexlansoprazole (82%) and those receiving placebo (87%) (Fig. [2](#Fig2){ref-type="fig"}b). In contrast, a larger difference in maintenance rates between dexlansoprazole and placebo was observed among patients with EE of grade B (82% with dexlansoprazole vs. 13% with placebo). One patient with EE of grade C at baseline who received placebo did not maintain healing.

Similar to results observed in the open-label healing phase, daytime heartburn was more common than nighttime heartburn in the maintenance phase. The median percentage of days without daytime heartburn was 89.7% in the dexlansoprazole group and 82.7% in the placebo group, while the median percentage of days without nighttime heartburn was 95.6% in the dexlansoprazole group and 90.3% in the placebo group. Heartburn (either daytime or nighttime) was absent for a median of 86.6% and 68.1% of days for the dexlansoprazole and placebo groups, respectively. The differences between the dexlansoprazole and placebo groups were not statistically significant.

### Treatment-Free Follow-up Phase {#Sec12}

Patients with healed EE at the end of the maintenance phase discontinued study drug before entering the follow-up phase. During the 3-month follow-up period, patients who had previously received dexlansoprazole or placebo had neither daytime nor nighttime heartburn for a median of 86.3% and 83.6% of days, respectively. No patients experienced a recurrence of symptoms that required an invasive procedure or treatment with a PPI or H2RA during the follow-up period; however, a study-drug-related reoccurrence of GERD was reported as an adverse event for 1 patient receiving dexlansoprazole during the maintenance phase. This patient was subsequently given omeprazole.

Median heartburn severity scores during daytime, nighttime, or both daytime and nighttime were no greater than 0.4 (on a scale of 0--3) during all phases, indicating that most patients classified their heartburn as "not hurting very much." Patients in the dexlansoprazole and placebo groups did not use rescue medication for a median of 99.1% and 97.7% of days, respectively, during the double-blind phase. During the follow-up phase, the need for rescue medication remained infrequent, with a median of 96.9% and 100.0% of days without rescue medication observed in the dexlansoprazole and placebo groups, respectively.

Discussion {#Sec13}
==========

The prevalence of EE increases progressively with age, and young people with chronic reflux disease may eventually develop esophageal mucosa complications similar to those in adults \[[@CR8], [@CR13], [@CR29]\]. For pediatric patients in general, common reflux symptoms include regurgitation, cough, epigastric pain, and heartburn \[[@CR2]\]. In adolescents, heartburn and regurgitation---which are the primary symptoms indicating GERD in adults---become more prevalent \[[@CR1], [@CR30]\]. Currently, PPIs are the treatment of choice for relief of GERD symptoms and healing of EE in adults \[[@CR30]\], and are recommended as first-line therapy in children with EE \[[@CR1]\].

This study demonstrated that the safety and tolerability of dexlansoprazole in adolescents were consistent with the safety and tolerability profile observed in adults \[[@CR31]\]. The majority of reported TEAEs for dexlansoprazole were mild in severity, with headache the most commonly reported AE by adolescent patients receiving either 30 mg or 60 mg of dexlansoprazole. Discontinuations were rare; only one patient discontinued the study because of an AE of GERD, suggesting that this patient may have experienced an inadequate response to dexlansoprazole.

In our study, dexlansoprazole resulted in an EE healing rate in adolescents of 88%, comparable to that previously observed in adults (85% and 87%) \[[@CR21]\]. A notable difference between the adolescent and adult studies, however, was that a greater proportion of adolescents (82%) maintained EE healing with 16 weeks of continued dexlansoprazole treatment than that observed in adults (66%) who received maintenance dexlansoprazole for 24 weeks. It is important to note that the patient population in the adult study had more severe EE (approximately 30% with grades C and D) than the adolescents in our study. Further, while the study durations were different, findings from a study by Boccia and colleagues suggested that children with uncomplicated GERD may not require maintenance therapy after EE healing \[[@CR16]\]. Based on the findings of Boccia and colleagues \[[@CR16]\] and to minimize placebo exposure, a shorter maintenance phase had been used in our adolescent study than that was used in the adult study. The numeric differences in EE healing rates between dexlansoprazole and placebo were notable but did not reach statistical significance; 58% of adolescent patients in the present study maintained EE healing with placebo, while in the adult study only 14% had remained healed with placebo treatment \[[@CR22]\]. The maintenance of healed EE after placebo treatment in pediatric patients and not in adults may be a reflection on age-related differences in the natural history of GERD. Conversely, this observation could represent the less severe GERD phenotype in the pediatric patient at the time of diagnosis and treatment initiation. As suggested by the literature, adolescent EE may be an earlier phase of the adult disease \[[@CR6]--[@CR8], [@CR32]\]. Consequently, once healed, adolescents may be less likely to relapse. In contrast, EE in adulthood may present with greater severity, as disease management may be further confounded by age-related increases in comorbid conditions and concomitant medication use that occurs with advancing age \[[@CR33]\].

Our subgroup analysis of adolescents by baseline LA grade provides further support for the hypothesis that the high placebo rates for maintaining healed EE are driven by less severe disease. Adolescents with EE grade A at baseline who achieved complete healing with dexlansoprazole 60 mg at week 8 appeared to maintain healed EE after dexlansoprazole was discontinued (i.e., after they were randomized to placebo). Adolescents with EE grade B appeared to benefit more from dexlansoprazole maintenance therapy; the difference in treatment was remarkably higher in those with EE grade B (82% maintained healing with dexlansoprazole and only 13% with placebo) than in those with EE grade A (87% maintained healing with dexlansoprazole and 81% with placebo). These findings contradict the study by Boccia et al. who reported sustained EE healing in 97.8% of children with all grades of EE, regardless of whether they were on placebo or PPI treatment \[[@CR16]\]. A limitation of our study is the lack of a significant proportion of patients with EE of grade C or D, which could demonstrate that more severely affected adolescents respond better to maintenance therapy with dexlansoprazole. Another limitation of this study is the lack of independent blinded grading verification of the endoscopy readouts generated at the trial sites. Relying solely on readings by one endoscopist may have resulted in overestimation of EE occurrences at diagnosis, particularly low-grade EE. In turn, this observation could partially explain the high rate of healing and maintained healing in patients with EE grade A diagnosis, and the parity of results with placebo and dexlansoprazole in this subset of patients, since some of them may not have had actual EE.

In summary, this study supports the use of dexlansoprazole as a treatment option for EE: dexlansoprazole was generally safe and resulted in a numerically greater rate of maintenance of healed EE in adolescent patients compared with placebo. Overall, the results suggest that adolescents with mild EE (grade A) appeared more likely to maintain healed EE than those with higher-grade EE and that dexlansoprazole may provide greater maintenance benefit than placebo in patients with more severe disease.
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